Pacira Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 28, 2026, reports a material definitive agreement entered into by Pacira Biosciences, Inc. (the "Company"). The filing details the divestiture of the Company's handheld cryoanalgesia business, including the iovera® product line, to Zimmer, Inc., a subsidiary of Zimmer Biomet Holdings, Inc.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for the reporting period. The primary financial data relates to the transaction structure:
- Total Consideration: Up to $140.0 million.
- Upfront Payment: $70.0 million, subject to customary adjustments for cash, accounts receivable, indebtedness, transaction expenses, and inventory.
- Contingent Consideration: Up to an additional $70.0 million payable based on revenue milestones achieved between January 1, 2027, and December 31, 2031.
- Workforce Impact: Approximately 66 employees (8% of total workforce) are expected to be hired by the Purchaser.
Material Changes and Milestones
The transaction represents a significant change in the Company's asset base and revenue streams, specifically the removal of the handheld cryoanalgesia segment. The contingent consideration is tied to the following net revenue thresholds for the "Business Products" in any single calendar year from 2027 to 2031:
- $50.0 million threshold: Triggers $18.5 million payment.
- $60.0 million threshold: Triggers $23.5 million payment.
- $70.0 million threshold: Triggers $28.0 million payment.
The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.
Outlook, Risks, and Management Commentary
Management has agreed to post-closing restrictive covenants, including non-competition, non-solicitation, non-disparagement, and confidentiality obligations. The filing notes that the Purchase Agreement contains customary representations and warranties, which are qualified by confidential disclosure schedules and should not be relied upon as characterizations of the actual state of facts. The full text of the Purchase Agreement will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the period ending June 30, 2026.
Key Facts for Investor Verification
- Verify the final closing date and any adjustments to the $70.0 million upfront payment upon closing in Q3 2026.
- Monitor the Company's future 10-Q and 10-K filings for the impact of the divestiture on consolidated revenue and operating expenses.
- Track the performance of the divested iovera® business to assess the likelihood of achieving the $50M, $60M, or $70M revenue milestones for contingent payments.
- Review the full Purchase Agreement (Exhibit 10 to the upcoming 10-Q) for specific details on indemnification and restrictive covenants.